Skip to content
Vasopressin
Vasostrict (vasopressin) is a protein pharmaceutical. Vasopressin was first approved as Vasostrict on 2014-04-17.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vasostrict (generic drugs available since 2021-12-15)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vasopressin
Tradename
Company
Number
Date
Products
VASOPRESSINAmerican RegentN-212593 RX2020-08-03
1 products, RLD, RS
VASOSTRICTPar PharmaceuticalN-204485 RX2014-04-17
6 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vasopressinNew Drug Application2023-01-01
vasostrictNew Drug Application2023-06-01
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Vasopressin, Vasostrict, Par Sterile Products
93754782035-01-30U-1857
96875262035-01-30U-1857
97442092035-01-30U-1857
97442392035-01-30U-1857
97507852035-01-30DP
99190262035-01-30DP
99252332035-01-30U-1857
99252342035-01-30U-1857
99372232035-01-30U-1857
99624222035-01-30U-1857
99686492035-01-30U-1857
99748272035-01-30U-1857
99810062035-01-30U-1857
100105752035-01-30U-1857
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03X: Other diuretics in atc
— C03XA: Vasopressin antagonists, diuretics
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BA: Vasopressin and analogues
— H01BA01: Vasopressin (argipressin)
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C67—32——4
Carcinoma in situD002278D09.9—12——2
Transitional cell carcinomaD002295——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urologic neoplasmsD014571C64-C681————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVASOPRESSIN
INNvasopressin injection
Description
Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+).
Classification
Protein
Drug classvasoconstrictors (vasopressin derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Identifiers
PDB—
CAS-ID113-79-1
RxCUI—
ChEMBL IDCHEMBL373742
ChEBI ID34543
PubChem CID644077
DrugBankDB00067
UNII IDY87Y826H08 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vasopressin - Eagle Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 51,846 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
166 adverse events reported
View more details